205 related articles for article (PubMed ID: 26586936)
1. Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.
Zhang L; Tong Y; Zhang X; Pan M; Chen S
Drug Des Devel Ther; 2015; 9():5851-62. PubMed ID: 26586936
[TBL] [Abstract][Full Text] [Related]
2. Arsenic sulfide amplifies JQ1 toxicity via mitochondrial pathway in gastric and colon cancer cells.
Tan Z; Zhang X; Kang T; Zhang L; Chen S
Drug Des Devel Ther; 2018; 12():3913-3927. PubMed ID: 30532520
[TBL] [Abstract][Full Text] [Related]
3. Arsenic sulfide, the main component of realgar, a traditional Chinese medicine, induces apoptosis of gastric cancer cells in vitro and in vivo.
Zhang L; Tian W; Kim S; Ding W; Tong Y; Chen S
Drug Des Devel Ther; 2015; 9():79-92. PubMed ID: 25565771
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2.
Xu HB; Shen FM; Lv QZ
Eur J Pharmacol; 2015 Dec; 769():1-7. PubMed ID: 26407653
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro.
Chung WH; Sung BH; Kim SS; Rhim H; Kuh HJ
Int J Oncol; 2009 Jun; 34(6):1669-79. PubMed ID: 19424586
[TBL] [Abstract][Full Text] [Related]
6. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
LaBonte MJ; Manegold PC; Wilson PM; Fazzone W; Louie SG; Lenz HJ; Ladner RD
Int J Cancer; 2009 Dec; 125(12):2957-69. PubMed ID: 19536776
[TBL] [Abstract][Full Text] [Related]
7. Arsenic sulfide inhibits cell migration and invasion of gastric cancer in vitro and in vivo.
Zhang L; Kim S; Ding W; Tong Y; Zhang X; Pan M; Chen S
Drug Des Devel Ther; 2015; 9():5579-90. PubMed ID: 26487802
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
9. Tetraarsenictetrasulfide and Arsenic Trioxide Exert Synergistic Effects on Induction of Apoptosis and Differentiation in Acute Promyelocytic Leukemia Cells.
Wang S; Zhou M; Ouyang J; Geng Z; Wang Z
PLoS One; 2015; 10(6):e0130343. PubMed ID: 26110921
[TBL] [Abstract][Full Text] [Related]
10. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan.
Liu X; Guo WJ; Zhang XW; Cai X; Tian S; Li J
Cancer Chemother Pharmacol; 2011 Oct; 68(4):871-8. PubMed ID: 21286718
[TBL] [Abstract][Full Text] [Related]
12. Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.
Bijman MN; Hermelink CA; van Berkel MP; Laan AC; Janmaat ML; Peters GJ; Boven E
Biochem Pharmacol; 2008 Jan; 75(2):427-37. PubMed ID: 17936723
[TBL] [Abstract][Full Text] [Related]
13. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
[TBL] [Abstract][Full Text] [Related]
14. Arsenic sulfide as a potential anti‑cancer drug.
Ding W; Zhang L; Kim S; Tian W; Tong Y; Liu J; Ma Y; Chen S
Mol Med Rep; 2015 Feb; 11(2):968-74. PubMed ID: 25371265
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer.
Lin XM; Li S; Zhou C; Li RZ; Wang H; Luo W; Huang YS; Chen LK; Cai JL; Wang TX; Zhang QH; Cao H; Wu XP
Int J Biochem Cell Biol; 2019 Nov; 116():105610. PubMed ID: 31518663
[TBL] [Abstract][Full Text] [Related]
16. AEE788 potentiates celecoxib-induced growth inhibition and apoptosis in human colon cancer cells.
Venkatesan P; Bhutia SK; Singh AK; Das SK; Dash R; Chaudhury K; Sarkar D; Fisher PB; Mandal M
Life Sci; 2012 Oct; 91(15-16):789-99. PubMed ID: 22922496
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of the BET protein inhibitor JQ1 in cisplatin-induced nephrotoxicity.
Sun L; Liu J; Yuan Y; Zhang X; Dong Z
Am J Physiol Renal Physiol; 2018 Sep; 315(3):F469-F478. PubMed ID: 29767555
[TBL] [Abstract][Full Text] [Related]
18. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
Pencreach E; Guérin E; Nicolet C; Lelong-Rebel I; Voegeli AC; Oudet P; Larsen AK; Gaub MP; Guenot D
Clin Cancer Res; 2009 Feb; 15(4):1297-307. PubMed ID: 19190131
[TBL] [Abstract][Full Text] [Related]
19. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens.
Swamy MV; Cooma I; Reddy BS; Rao CV
Int J Oncol; 2002 Apr; 20(4):753-9. PubMed ID: 11894121
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib enhanced the cytotoxic effect of cisplatin in chemo-resistant gastric cancer xenograft mouse models through a cyclooxygenase-2-dependent manner.
Xu HB; Shen FM; Lv QZ
Eur J Pharmacol; 2016 Apr; 776():1-8. PubMed ID: 26879869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
